Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 8/20 | 0.58 |
| ▸ | DRD2 | P14416 | 7/20 | 0.58 |
| ▸ | CCR3 | P51677 | 1/20 | 0.52 |
| ▸ | DRD4 | P21917 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | SMYD2 | Q9NRG4 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14006132 | 0.88 | DRD2 (0.59) | DRD3DRD2CCR3DRD4SMYD2 | |
| SCHEMBL14005928 | 0.85 | DRD3 (0.63) | DRD3DRD2DRD4CYP1A2MAPT | |
| SCHEMBL14006045 | 0.82 | DRD3 (0.59) | DRD3DRD2DRD4CYP1A2MAPT | |
| SCHEMBL14006044 | 0.80 | DRD2 (0.61) | DRD3DRD2DRD4CYP1A2MAPT | |
| SCHEMBL14006130 | 0.79 | DRD2 (0.63) | DRD3DRD2DRD4CYP1A2MAPT | |
| SCHEMBL4910001 | 0.78 | DRD2 (0.67) | DRD3DRD2DRD4MAPTSMN1; SMN2 | |
| SCHEMBL14005944 | 0.77 | DRD2 (0.51) | DRD3DRD2CCR3DRD4CYP1A2 | |
| SCHEMBL14006134 | 0.77 | BCHE (0.48) | DRD3DRD2CCR3MAPTSMYD2 | |
| SCHEMBL14005931 | 0.75 | HDAC2 (0.56) | DRD3DRD2DRD4CYP1A2MAPT | |
| SCHEMBL14005934 | 0.75 | DRD3 (0.67) | DRD3DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275028-A1 | Modulators or Alpha7 Nicotinic Acetylcholine Receptors and Therapeutic Uses Thereof | SIENA BIOTECH S.P.A. (IT) | 2008-11-06 | — | — | US | disclosed |
| US-20080275028-A1 | Modulators or Alpha7 Nicotinic Acetylcholine Receptors and Therapeutic Uses Thereof | SIENA BIOTECH S.P.A. (IT) | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275028-A1 | Modulators or Alpha7 Nicotinic Acetylcholine Receptors and Therapeutic Uses Thereof | CHRNA7, CHRNA5, CHRNA1 | DRD3 597/4885DRD2 582/4885CCR3 763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.